Computational systems biology approaches to anti-angiogenic cancer therapeutics

被引:39
|
作者
Finley, Stacey D. [1 ]
Chu, Liang-Hui [2 ]
Popel, Aleksander S. [2 ]
机构
[1] Univ So Calif, Dept Biomed Engn, Los Angeles, CA 90089 USA
[2] Johns Hopkins Univ, Sch Med, Dept Biomed Engn, Baltimore, MD 21205 USA
关键词
ENDOTHELIAL GROWTH-FACTOR; METALLOPROTEINASE MMP 2; ANTIANGIOGENIC THERAPY; MATHEMATICAL-MODEL; COLLAGEN-IV; TUMOR MICROENVIRONMENT; MONOCLONAL-ANTIBODY; TREATMENT RESPONSE; SIGNALING PATHWAY; VEGF;
D O I
10.1016/j.drudis.2014.09.026
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. Anti-angiogenic therapy involves inhibiting multiple cell types, molecular targets, and intracellular signaling pathways. Computational tools are useful in guiding treatment strategies, predicting the response to treatment, and identifying new targets of interest. Here, we describe progress that has been made in applying mathematical modeling and bioinformatics approaches to study anti-angiogenic therapeutics in cancer.
引用
收藏
页码:187 / 197
页数:11
相关论文
共 50 条
  • [1] Anti-Angiogenic Peptides for Cancer Therapeutics
    Rosca, Elena V.
    Koskimaki, Jacob E.
    Rivera, Corban G.
    Pandey, Niranjan B.
    Tamiz, Amir P.
    Popel, Aleksander S.
    [J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY, 2011, 12 (08) : 1101 - 1116
  • [2] Anti-angiogenic drugs in cancer therapeutics: a review of the latest preclinical and clinical studies of anti-angiogenic agents with anticancer potential
    Vafopoulou, Polyxeni
    Kourti, Malamati
    [J]. JOURNAL OF CANCER METASTASIS AND TREATMENT, 2022, 8
  • [3] Emerging immunologic approaches as cancer anti-angiogenic therapies
    Azimi, Mohammadreza
    Manavi, Mahdokht Sadat
    Afshinpour, Maral
    Khorram, Roya
    Vafadar, Reza
    Rezaei-Tazangi, Fatemeh
    Arabzadeh, Danyal
    Arabzadeh, Sattar
    Ebrahimi, Nasim
    Aref, Amir Reza
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [4] Mushroom: A New Resource for Anti-Angiogenic Therapeutics
    Jana, Pradipta
    Acharya, Krishnendu
    [J]. FOOD REVIEWS INTERNATIONAL, 2022, 38 (01) : 88 - 109
  • [5] Angiogenesis inhibitors and the need for anti-angiogenic therapeutics
    Dass, C. R.
    Tran, T. M. N.
    Choong, P. F. M.
    [J]. JOURNAL OF DENTAL RESEARCH, 2007, 86 (10) : 927 - 936
  • [6] Anti-Angiogenic Approaches to Malignant Gliomas
    Soffietti, R.
    Trevisan, E.
    Bertero, L.
    Bosa, C.
    Ruda, R.
    [J]. CURRENT CANCER DRUG TARGETS, 2012, 12 (03) : 279 - 288
  • [7] Dieckol as a novel anti-proliferative and anti-angiogenic agent and computational anti-angiogenic activity evaluation
    Li, Yong-Xin
    Li, Yong
    Je, Jae-Young
    Kim, Se-Kwon
    [J]. ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY, 2015, 39 (01) : 259 - 270
  • [8] Cancer anti-angiogenic therapy
    Shimizu, K
    Oku, N
    [J]. BIOLOGICAL & PHARMACEUTICAL BULLETIN, 2004, 27 (05) : 599 - 605
  • [9] VEGF-A splicing: the key to anti-angiogenic therapeutics?
    Steven J. Harper
    David O. Bates
    [J]. Nature Reviews Cancer, 2008, 8 : 880 - 887
  • [10] VEGF-A splicing: the key to anti-angiogenic therapeutics?
    Harper, Steven J.
    Bates, David O.
    [J]. NATURE REVIEWS CANCER, 2008, 8 (11) : 880 - 887